248: Drugs, surgeries, and shortages: the state of obesity care in 2025

In 2025, 6% of US adults are taking a GLP-1. But the popularity of weight-loss drugs isn’t the only thing changing the obesity care landscape. On Radio Advisory, we’ve talked about what comprehensive obesity care looks like, the reality of weight bias, and the strain high-cost drugs like GLP-1s are having on employers and plans. But we haven’t done an updated scan of the obesity care landscape, until now. To share the state of the Obesity market in 2025, host Rachel (Rae) Woods invites Advisory Board experts Gaby Marmolejos and Madeline Vogel to share the latest on bariatric surgery volumes, coverage decisions, patient preferences, drug shortages, compounding, and the new competitive landscape for direct-to-consumer obesity care. Given the pace of change in just a few short years, Rae also invites her guests make predictions about the obesity market two years from now. Links: Ep. 159: Ozempic, Wegovy, and our questions on weight management drugs Ep. 222: It's not just GLP-1s; here's what comprehensive weight management looks like Diabetes and obesity care growth forecast: What you need to know GLP-1 innovation showcase 2025 Nursing Survey Upcoming Webinar: Obesity market trends and forecasts A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.